Lipanthyl Supra (Fenofibrate)

Fenofibrate activates the nuclear receptor PPARα, which increases the oxidation of fatty acids and reduces the synthesis of triglycerides in the liver. This action accelerates the clearance of triglyceride‑rich lipoproteins from the bloodstream and modestly raises HDL‑cholesterol, resulting in a more favorable lipid profile.

The specific dose of Lipanthyl Supra is determined by the prescribing clinician based on the patient’s clinical condition, laboratory values, and concomitant therapies. Healthcare professionals tailor the regimen to achieve optimal lipid control while considering safety and tolerability.

Fenofibrate is generally not recommended during pregnancy or lactation unless the potential benefit justifies the potential risk to the fetus or infant. Physicians should evaluate the individual situation and discuss alternative lipid‑lowering strategies when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Lipanthyl Supra. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to fenofibrate is the statin class, which primarily lowers LDL‑cholesterol. Fenofibrate is more effective at reducing triglycerides and modestly raising HDL‑cholesterol, making it suitable for patients with pronounced hypertriglyceridaemia or mixed dyslipidaemia, often in combination with a statin for comprehensive lipid management.

Store Lipanthyl Supra at ambient temperature below 25 °C, in the original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments to maintain stability.

Lipanthyl Supra is taken orally, usually with a meal to enhance absorption. Patients should swallow the tablet whole with water and follow the dosing schedule prescribed by their healthcare provider.

Serious adverse events include rhabdomyolysis or severe myopathy, especially when combined with certain statins, acute liver injury, pancreatitis, severe allergic reactions, and rare cases of renal dysfunction. Patients should report unexplained muscle pain, dark urine, jaundice, or persistent abdominal pain promptly.

Lipanthyl Supra is contraindicated in patients with active liver disease, severe renal impairment, known hypersensitivity to fenofibrate or other fibrates, and in individuals with gallbladder disease that may predispose to pancreatitis. Caution is also advised for patients on interacting medications such as high‑dose gemfibrozil or cyclosporine.